Repligen (RGEN) AI Stock Analysis

• Market Cap: $7.13B
• Dividend Yield: N/A
• Average Volume (3M): 719.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: 4.88%
• EPS Growth: -196.93%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.39
• Shares Outstanding: 56,183,100
• 10 Day Avg. Volume: 811,807
• 30 Day Avg. Volume: 719,606
• PEG Ratio: 1.15
• Price to Book (P/B): 23.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 242.40
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 3.73
• Enterprise Value/Gross Profit: 33.67
• Enterprise Value/Ebitda: 22.91
• 1Y Price Target: $181.27
• Price Target Upside: 42.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14

• Rating: 56 Neutral
• Price Target: $134.00 ▲(5.55%Upside)

Repligen's overall stock score reflects a balanced view of its current financial and market conditions. Strengths include a solid balance sheet and optimistic earnings guidance, contrasted by profitability challenges and technical indicators suggesting potential price pressure. Valuation remains a concern due to negative earnings and lack of dividend yield. The earnings call provides a positive outlook, mitigating some financial and valuation concerns. The overall score suggests caution with optimism for future growth.

Positive Factors

Financial Performance

Repligen recorded 1Q25 revenue totaling $169.2M, slightly better than the original top-line forecast of $165M.

Order Momentum

Repligen's order momentum is strong, with orders up high-teens and increasing quarter over quarter.

Revenue Growth

Repligen has favorably revised its top-line guidance for 2025 to a range of $695M to $720M, up from the prior $685-710M.

Negative Factors

Earnings Guidance

Repligen expects full-year 2025 GAAP net earnings of $0.76 - $0.85 per diluted share, down from the original guidance range of $0.90 - $0.99 per diluted share.

Market Conditions

Uncertainty regarding current market and economic conditions, including tariff and Forex issues, is leading to a Hold rating on RGEN shares.

Valuation

The company's valuation levels are considered a bit rich at this point.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation is a bioprocessing-focused company that develops and commercializes highly innovative products used in the process of manufacturing biologic drugs. It operates primarily in the life sciences sector, serving biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). The company's core products include protein A ligands, cell culture growth factors, and filtration products that are critical in the production of monoclonal antibodies and other biotherapeutics.

How the Company Makes Money

Repligen makes money through the sale of its bioprocessing products and technologies to biopharmaceutical companies and CDMOs. The company's revenue model is based on selling consumables and equipment used in the manufacturing of biologic drugs. Key revenue streams include its filtration products, which are used in the purification process, and its chromatography and protein A products, which are essential in the separation and purification of proteins. Repligen's earnings are also supported by strategic partnerships with leading biopharmaceutical companies and a focus on innovation in bioprocessing technologies, which help to ensure a steady demand for its products as the biopharmaceutical industry continues to grow.

Repligen Financial Statement Overview

Summary

Repligen shows a mixed financial performance with strong balance sheet indicators like low leverage and a healthy equity ratio. However, profitability issues are evident due to negative net income and EBIT margins, although operational efficiency is suggested by a positive EBITDA margin. Cash flow is positive, despite a decrease in free cash flow, highlighting operational resilience amidst profitability challenges.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	645.66M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	275.86M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	118.93M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-25.37M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.85B	2.83B	2.83B	2.52B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	697.23M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	683.70M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	866.66M	856.95M	866.34M	613.96M	608.29M	373.74M
Stockholders Equity	1.99B	1.97B	1.97B	397.27M	1.75B	65.77M
Cash Flow
Free Cash Flow	117.60M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	145.69M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.13M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-78.96M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 126.96
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Neutral. The current price of 126.96 is above the 20-day moving average (MA) of 125.67, below the 50-day MA of 128.31, and below the 200-day MA of 141.34, indicating a neutral trend. The MACD of -0.58 indicates Negative momentum. The RSI at 53.20 is Neutral, neither overbought nor oversold. The STOCH value of 72.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	76 Outperform	$5.53B	45.86	9.16%	―	8.24%	18.54%
STVN	74 Outperform	$6.68B	49.62	9.08%	0.25%	2.84%	-11.34%
ICUI	66 Neutral	$3.35B	―	-4.62%	―	7.19%	-56.19%
MASI	63 Neutral	$9.29B	116.65	-23.93%	―	-0.12%	-713.82%
TFX	58 Neutral	$5.37B	38.32	3.48%	1.12%	0.29%	-48.98%
RGEN	56 Neutral	$7.13B	―	-1.16%	―	4.88%	-196.93%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%

Repligen Corporate Events

Repligen Holds Annual Shareholders Meeting, Key Decisions Made

On May 15, 2025, Repligen Corporation held its Annual Meeting of Shareholders, where several key decisions were made. The shareholders elected ten directors to the board, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved the compensation of the company’s executive officers, and sanctioned an amendment to the Certificate of Incorporation to limit the liability of certain officers. These decisions are expected to influence Repligen’s governance and operational strategies moving forward.

The most recent analyst rating on (RGEN) stock is a Buy with a $225.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.